Sensei Biotherapeutics Inc (SNSE) Stock Price, Quote & News

Company Profile

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune ch...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 243 8000

Website: www.senseibio.com

Address:

1405 Research Boulevard, Suite 125, Rockville, United States

HegemonyHedge Dec. 24 at 12:24 PM

$SNSE Forward visibility remains uneven as strategic priorities translate into measurable operating outcomes. Delays or dilution could materially reshape the risk profile.

0 · Reply

joe77w Dec. 24 at 7:17 AM

$SNSE I believe It Is only a matter of weeks before a change of control occurs, ultra low float, 20/30 USD not impossible Co Is plenty of cash more than twice current market cap, seeking strategic alternatives... Retention agreemeent with Key date late february hmmm Do your dd before INVESTING your Money, Just my opinion not a FINANCIAL advice https://www.otcmarkets.com/filing/html?id=19019836&guid=Okt-kpu8ZQSC4Vh

0 · Reply

JohnTrack Dec. 24 at 12:36 AM

$SNSE watching, nothing committed!

0 · Reply

JohnTrack Dec. 23 at 10:31 PM

$SNSE update just filed on the wire https://www.rapidticker.com/news/snse-sec-filing-87ffe9

0 · Reply

TrueWinner786 Dec. 23 at 5:07 PM

$SNSE another great stock is $ATHA huge potential after the last exclusive licensing news.

0 · Reply

Dkpatel62 Dec. 22 at 1:42 PM

$SNSE looks like making money from manipulating the stocks only Need to be investigated

0 · Reply

SmartMoneyTradez Dec. 18 at 4:34 PM

$SNSE A matter of time

0 · Reply

Dkpatel62 Dec. 17 at 4:39 PM

$SNSE looks like dummy company

0 · Reply

Dkpatel62 Dec. 17 at 3:28 PM

$SNSE cheater Be careful

1 · Reply

TapeLite_1778 Dec. 17 at 11:01 AM

$SNSE thin biotech sitting on support, watch for a higher low and a single big volume day as shift in control

0 · Reply

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 9:00 AM EDT - 2 months ago

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

Oct 17, 2025, 8:00 AM EDT - 2 months ago

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

Sep 23, 2025, 7:30 AM EDT - 3 months ago

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

Sep 3, 2025, 8:00 AM EDT - 4 months ago

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 5, 2025, 7:30 AM EDT - 5 months ago

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 30, 2025, 7:30 AM EDT - 5 months ago

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Jun 13, 2025, 7:30 AM EDT - 6 months ago

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

May 6, 2025, 7:30 AM EDT - 8 months ago

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Apr 2, 2025, 7:30 AM EDT - 9 months ago

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 28, 2025, 7:30 AM EDT - 9 months ago

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Mar 27, 2025, 4:05 PM EDT - 9 months ago

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Feb 4, 2025, 7:30 AM EST - 11 months ago

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Nov 27, 2024, 4:05 PM EST - 1 year ago

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Upcoming Conferences

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 30, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

May 23, 2024, 5:10 PM EDT - 1 year ago

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

May 10, 2024, 11:45 AM EDT - 1 year ago

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

May 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Apr 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Apr 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Mar 22, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Mar 6, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Feb 28, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Nov 7, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 3, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Oct 25, 2023, 9:05 AM EDT - 2 years ago

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Oct 23, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

Sep 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sep 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

Aug 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 2, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference

Jun 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”

Jun 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

May 9, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Apr 20, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Apr 18, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Cantor Fitzgerald's Future of Oncology Virtual Symposium

Mar 28, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

Mar 21, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Mar 14, 2023, 4:35 PM EDT - 3 years ago

Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023

HegemonyHedge Dec. 24 at 12:24 PM

$SNSE Forward visibility remains uneven as strategic priorities translate into measurable operating outcomes. Delays or dilution could materially reshape the risk profile.

0 · Reply

joe77w Dec. 24 at 7:17 AM

0 · Reply

JohnTrack Dec. 24 at 12:36 AM

$SNSE watching, nothing committed!

0 · Reply

JohnTrack Dec. 23 at 10:31 PM

$SNSE update just filed on the wire https://www.rapidticker.com/news/snse-sec-filing-87ffe9

0 · Reply

TrueWinner786 Dec. 23 at 5:07 PM

$SNSE another great stock is $ATHA huge potential after the last exclusive licensing news.

0 · Reply

Dkpatel62 Dec. 22 at 1:42 PM

$SNSE looks like making money from manipulating the stocks only Need to be investigated

0 · Reply

SmartMoneyTradez Dec. 18 at 4:34 PM

$SNSE A matter of time

0 · Reply

Dkpatel62 Dec. 17 at 4:39 PM

$SNSE looks like dummy company

0 · Reply

Dkpatel62 Dec. 17 at 3:28 PM

$SNSE cheater Be careful

1 · Reply

TapeLite_1778 Dec. 17 at 11:01 AM

$SNSE thin biotech sitting on support, watch for a higher low and a single big volume day as shift in control

0 · Reply

rangervs Dec. 12 at 4:06 PM

$OCG they pushed it down to 52 week low and then blast off! $SNSE waiting game for $10+ again

0 · Reply

Gretzky121212 Dec. 12 at 2:37 AM

$SNSE market caps 10 million cash on hand 25,000,000+ intellectual property, which is pretty important to tumor delivery so very possibhe company could get purchased! The company said no announcements will take place until required by law and any possible deals finalize.

0 · Reply

HuhereChapter11 Dec. 12 at 12:33 AM

$BYND $ONDS $SNSE $BBGI FO dip 💩! 🖕🤡🖕 Literally EVERY ticker you promote is a dilution SCAM!

0 · Reply

Myway1000 Dec. 11 at 5:44 PM

$PETS You better buy $SNSE. No volume. :)

0 · Reply

rangervs Dec. 11 at 5:31 PM

$SNSE push this over $10!

0 · Reply

vr2020vision Dec. 11 at 12:56 AM

$SNSE even sensei woke up today after the fall from 12$..well let's see

1 · Reply

petersadick Dec. 10 at 5:41 PM

$SNSE was management the ones that caused this to be the worst pump and dump i have ever experienced?

0 · Reply

invinc1ble Dec. 10 at 5:26 PM

You didnt buy when i alerted $BYND You didnt buy when i alerted $ONDS You didn’t buy when I alerted $SNSE You didn’t buy when I alerted $BBGI When will you begin to listen? 💎 $SPY --- momentum

1 · Reply

Zurb88 Dec. 10 at 2:00 PM

$SNSE $ADVB

0 · Reply

BozoJoeClownShow Dec. 10 at 1:33 PM

$SNSE 🤡🤡🤡🤡🤡🤡🤡🤡

0 · Reply

Mastertrader80 Dec. 10 at 3:04 AM

$SMX $ASST $SNSE $TWG . $AFJK $TGL A lot of fake gurus popping up saying they called smx and tgl haha yet no proof ! I actually Called smx at 5.50 sold at 415 !! 👀 £600000 profit in 4 days !!!!! https://www.launchpass.com/master-traders-server There was a gap in the chart at 382 the chart said that’s where it was going and that’s where it went 🚀 Follow me and join my free telegram to get access too the discord where we actually do call big runners and have the proof to back it :) link in my bio ! 📈 🚀$SMX

0 · Reply

Chrissytina Dec. 9 at 1:36 PM

$SNSE You know it’s a pump and dump when you see people pumping 3/4 other stocks here! Typical flips on a bio stock!

0 · Reply

Market Cap	11.62M
Revenue (ttm)	0.00
Net Income (ttm)	-30.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,800
Avg Vol	84,368
Day's Range	N/A - N/A
Shares Out	1.26M
Stochastic %K	81%
Beta	0.32
Analysts	Hold
Price Target	$35.00